Purpose: The objective of this study is to perform a systematic review and provide an update on the diagnosis and management of retinopathy associated with incontinentia pigmenti (IP). Design: This is a systematic review. Methods: A literature search was performed for articles related to IP-associated retinopathy on PubMed, Embase, and ScienceDirect with no date limitations. Articles published on ophthalmology journals were screened and original human studies pertaining to the diagnosis and management of IP retinopathy were included for data analysis. The clinical and imaging findings, treatment, follow-up frequency and duration, and final visual outcomes were recorded. Results: The literature search retrieved 388 articles across the databases. Forty-two full-text peer-reviewed original human studies, containing 100 eyes of 60 unique patients of IP retinopathy, met our inclusion criteria. The majority of patients (68%) presented with IP retinopathy during the first 2 years of life, and 12 eyes of 8 patients who progressed from mild to severe IP retinopathy were all presented before the age of 4 months. Thirty-one (31%) eyes developed retinal detachment, 24 (24%) eyes had a final visual acuity of light perception or no light perception, and 14 (14%) eyes had a visual acuity of 20/50 or better. Conclusion: The results of this systematic review suggest that early detection and early frequent reevaluation of retinopathy in patients with IP in the first 2 years of life are key in obtaining optimal visual outcomes. Therefore, we propose an updated IP retinopathy management algorithm.
Introduction
Incontinentia pigmenti (IP) is a rare X-linked dominant genetic disorder known to be associated with a loss-of-function mutation of the inhibitor of nuclear factor kB kinase subunit g (IKBKG), also called NF-kB Essential Modulator (NEMO) gene located on the chromosome band Xq28. IKBKG protein plays a regulatory role in cell signal transduction pathway that is critical in the formation of ectodermal tissues found in multiple organ systems. 1 Although primarily exhibiting a stepwise progression of dermatologic pathology, the condition also manifests itself in the central nervous system, dental and oral structures, and in more than one-third of those affected, the ocular system. 2, 3 Incontinentia pigmenti is disproportionately diagnosed in females; however, males with XXY karyotype (Klinefelter syndrome) or mosaicism may also develop IP. To date, there have been less than 70 documented case reports of male infants diagnosed with IP. 4 Ocular abnormalities range from strabismus, microphthalmia, optic nerve atrophy, and congenital cataracts to far more common retinal anomalies such as incomplete vascularization leading to neovascularization, retinal hemorrhage, and retinal detachment (RD), as well as foveal hypoplasia or vascularized fovea. 2, 3 In this study, we focus on the retinal manifestation of the disorder and perform a systematic review on the management of retinopathy associated with IP.
Methods
Available data from the English literature concerning the diagnosis and management of IP-associated retinopathy were considered. A literature search was conducted on 3 databases: PubMed, Embase, and ScienceDirect with no date limitations, using the phrases "incontinentia pigmenti and retina" and "Bloch-Sulzberger syndrome and retina." The literature search yielded 388 articles, including 1 found through searching the references of the included papers. Duplicated references across databases, literature reviews, non-full-text, foreign language articles, articles that were not focused on the management of IP retinopathy, and multiple reports on the same patients were excluded. Original human studies published in ophthalmology journals were screened, yielding 42 peer-reviewed papers, containing 60 unique patient cases of 100 affected eyes with documentation of the diagnosis and treatment of IP retinopathy. The review and paper selection process are illustrated in Figure 1 . Data on included papers were collected in a Microsoft Office Excel 2016 spreadsheet, with the following columns: first author, the year of publication, type of publication, age and gender of patient, initial visual acuity, laterality of affected eye(s), clinical examination and ocular imaging findings, grade of the retinopathy on initial presentation, treatment of IP retinopathy, clinical course, including the follow-up frequency and duration, and final visual outcomes. Data were presented as frequencies in tables.
Results
The phenotype of IP retinopathy, similar to that of retinopathy of prematurity (ROP), can present as a range of severity depends on the disease progression. Based on the review of the literature and a previous grading by Holmström and Thorén, 5 we propose a modified grading of IP retinopathy, considering normal retinal findings as grade 0 as well as adding the foveal development abnormalities we observed in the literature to the grading. 2, 3 For the purpose of this review, we would like to summarize different severities of retinopathy observed in patients with IP in a grading system proposed in Table 1 . Grade 0 denotes the clinical finding of a normal retina, which was observed in 20 of 120 eyes in this study. The first grade of IP retinopathy usually presents as incomplete vascularization of the peripheral retina, which can then progress to neovascularization at the border of the vascular and avascular retina (grade 2). Retinal hemorrhage may also be evident on fundus examination during this grade. Without intervention, the disease often progresses to tractional or rhegmatogenous RD (grade 3). In missed cases, chronic RD or formation of a retrolental fibrosis membrane or mass marks the highest level of severity of this retinal condition (grade 4). The corresponding retinal findings with fundus photography and fluorescein angiography (FA) for each grade are illustrated in Figures 2-6 .
The details of the patient presentation, treatment, and visual outcome are summarized in Table 2 . Of all patients, 41 (68%) presented during their first 2 years of life, 13 (22%) in childhood, and 6 (10%) in adulthood. Female to male ratio was 57:3. better. For the 41 (68%) patients who presented prior to 2 years of age, the characteristics of patients who had a final visual acuity better than 20/50 were compared to those of patients who had a final acuity of LP or NLP (Table 3) . On initial presentation, 13 eyes of 11 patients had grade 3 IP retinopathy and 10 eyes of 10 patients had grade 4 IP retinopathy. Of the 13 eyes presented with grade 3 IP retinopathy, 5 were of patients of 2 years and younger and all of them progressed to grade 4 retinopathy with no treatment except 1 intraocular lens implantation. Six pediatric eyes (>2 years) were treated with enucleation (1), oral acetazolamide with a stable final visual acuity of 20/25 (2), vitrectomy and scleral buckle with progression to grade 4 retinopathy bilaterally (2) , and lastly a combination of laser photocoagulation, vitrectomy, and epiretinal membrane peel with success (1). Finally, 2 adult eyes were treated with laser photocoagulation with good results. On the other hand, 12 eyes of 8 patients, all presented in their first 4 months of life with grade 0 to grade 2 IP retinopathy, progressed to grade 3 or grade 4 eventually.
The most commonly employed monotherapy was observation (41), followed by laser photocoagulation (28), cryotherapy (9) , and enucleation (6) . Different combinations of vitreoretinal surgeries were used in 10 eyes, and cryotherapy was combined with vitrectomy with/without scleral buckle in 3 eyes. Observation and cryotherapy were more common treatment options in the cases published prior to the late 1990s. Laser photocoagulation treatment was not utilized until the late 1990s and early 2000s. Intravitreal anti-vascular endothelial growth factor (VEGF) was successfully used as either a sole treatment (1) or an adjunct (3) treatment with laser photocoagulation in recent years.
Discussion
Incontinentia pigmenti is a multisystem genomic disease that affects the neural crest-derived structures found in the skin, central nervous system, and dental, oral, and ocular systems. Ocular anomalies were found in 30.5% to 37.4% of patients with IP according to different studies. 3, 6 According to a metaanalysis by Minić et al, retinal anomalies were found in 17.52% of patients with IP investigated during the period between 1976 and 2010. 3 Watzke et al reported a case series of retinal vascular findings in 19 patients with IP, classifying retinal abnormalities as macular structural anomalies and/or peripheral vascular anomalies. 7 Peripheral vascular anomalies are similar to retinal findings in ROP and share similar course of disease that starts with a peripheral avascular zone to neovascularization at the border of vascular and avascular retina to finally progressing to tractional RD in untreated patients.
A loss-of-function mutation of the IKBKG or NEMO gene has been associated with over 80% of cases of IP. 8 The IKBKG gene encodes for a regulatory subunit of the IkB kinase complex, which is a required activator for the NF-kB, which then regulates target gene transcription in the nucleus. 1 In a large cohort genomic study of 122 unrelated patients with IP, ocular defects were found in 55% of patients with IKBKG point mutations versus 17% of patients with the classical deletion mutations (Dexon 4-10) of IKBKG gene. 1 This observation indicates that there is some degree of genotype and phenotype correlation in IP and that genetic testing could play a role in prognosis prediction and determining follow-up frequency in patients with IP retinopathy. However, genetic studies have demonstrated that there is a highly variable phenotype expression of IP with the same genotype even within the same family, due to X-inactivation and the pleiotropic role of the NEMO gene, and gene interactions with different genomic backgrounds. 9, 10 Based on a case series of the ocular findings in 30 patients with IP, Holmströ m and Thorén proposed a surveillance follow-up for managing ocular anomalies in newly diagnosed neonates with IP. They suggested that the patients to be examined soon after birth, followed with monthly reevaluation for the first 3 to 4 months, every 3-month evaluation for the first year, and semiannually up to age 3 years, with decreased follow-up intervals for patients with retinal abnormalities; if no ocular abnormalities are found by age 3, then regular follow-up can be discontinued. 5 O'Doherty et al described ocular manifestations in a case series of 11 patients with IP and claimed that the above follow-up schedule was too frequent for patients with initially normal retinal findings. They did, however, recommend following up on patients with abnormal retinal findings every 2 weeks for 3 months, followed with monthly checkup for 6 months and then every 3 months for 1 year. 11 In the same study, they reviewed 15 case series, which demonstrated that all of the RDs in patients with IP occurred within the first 18 months of life. Therefore, they made no specific suggestions on how often should clinicians follow on patients beyond 18 months of age. 11 While that finding is largely consistent with what we observed in the literature, there have been several reports on adult patients, who had no known ocular manifestations of IP, presented with RD. [12] [13] [14] [15] [16] In addition, spontaneous reattachment of RD in IP has been reported, and patients may experience fluctuation of visual acuity without being aware of their chronic or recurrent retinal lesions for years. 13 Thus, one should consider following these patients annually for their lifetimes.
Similar to the findings in previous literature reviews, the results of the current systematic review demonstrate that retinal manifestations can occur early in infancy in patients with IP and could lead to the RD and fibrosis if the condition is left untreated in a timely fashion. 3, 4, 15, 17 It is paramount for all patients with a diagnosis of IP in infancy to be evaluated by an ophthalmologist and have an examination under anesthesia (EUA) with FA as soon as the patient can safely receive general anesthesia to assess for abnormal retinal vasculature regardless of the clinical examination findings. The importance of FA in diagnosing IP retinopathy has been demonstrated repeatedly in the literature, as it can detect vascular changes that are otherwise missed on clinical examinations and on fundus photography. 4, 18, 19 In addition, FA is also essential in providing a roadmap for laser photocoagulation or other surgical treatment. 4, 15, 16, 20 Although EUA with FA has been the gold-standard approach for diagnosing retinal abnormalities in patients with IP, not all patients are able to undergo anesthesia or have access to EUA. Patel et al demonstrated in a case study that an in-office examination with noncontact ultra-wide-field retinal imaging using Optos P200MA (Dunfermline, Scotland) and FA can be an effective alternative. 21 Although most authors agree that patients with IP should be frequently reevaluated ophthalmologically in the first 2 years, there has been no universally agreed reexamination schedules that clinicians follow on these patients. As demonstrated in the characteristics of patients who presented before age 2 years in this study (Table 3) , early detection and treatment as well as frequent early reevaluations are associated with better visual outcomes, regardless of the form of treatment received. With a timely detection of the retinal symptoms, the progression of the disease can be mitigated or halted with prompt treatment. Based on the results, as well as previous reviews on the management of IP retinopathy, we propose an update in the management algorithm as shown in Figure 7 in order to help patients with IP achieve and maintain their best possible visual outcomes.
Regarding patients who are diagnosed with IP shortly after birth and who had normal retinal findings, or grade 0 IP retinopathy, on initial EUA with FA, the results of our current systematic review demonstrate that new onset of retinopathy appearing after the second year of life is unlikely. Because of this finding, we divided our follow-up algorithm based on the presence or absence of retinopathy on EUA with FA. With regard to those with absent retinopathy, determined by normal examination and FA, we would alter the follow-up schedule slightly to allow for annual visits from the age of 3 onward. The proposed management algorithm for patients without ocular abnormalities at initial visit includes repeat examinations every 3 months until age 1, semiannual visits through age 2, and then annual visits for life until more is known about the possibility of recurrence as an adult (Figure 7) . The decision of whether to treat grade 1 IP retinopathy is up to the provider. We tend to err on the side of treatment if there are areas of nonperfusion. Many authors suggest that early detection and treatment of retinal pathology can halt the progression to proliferative vasculopathy and tractional RD. 13 Studies have demonstrated that ocular stability is the norm once early laser surgical treatment is performed. 1, 6, 5 Nonetheless, there have been reports on recurrence of neovascularization post laser photocoagulation or cryotherapy. 22, 23 As part of posttreatment surveillance, we suggest that an infant patient who was treated with laser photocoagulation or cryotherapy should be reevaluated in 6 to 8 weeks with an examination using FA and repeat the treatment for a nonsatisfactory response. If one decides not to treat, we follow O'Doherty's recommendations for follow-up, with an addition of repeating the FP and FA in 3 months, once more till age 1 and at least once during the second year. The patient should be then reevaluated every 3 months for 1 year, semiannually until age 5, and then annually for the rest of their lives ( Figure 7) .
In terms of treatment for grade 2 proliferative retinopathy, the results of this systematic review suggest that laser photocoagulation therapy, followed by cryotherapy, is the most employed treatment of neovascularization. The first report on anti-VEGF as a therapy for IP retinopathy demonstrated regression of neovascularization, but the visual outcome was poor. 24 Intravitreal bevacizumab was used as an adjunct therapy with laser photocoagulation in 1 eye due to lack of view and as a sole therapy in 1 eye of the younger sister in the same study, both with good outcomes. 25 In another study, intravitreal ranibizumab was administrated as an adjunct therapy in 2 eyes of the same patient who was refractory to laser treatment and multiple recurrences of grade 2 IP retinopathy, with a good final visual outcome. 22 The use of anti-VEGF is still at the early grade as a sole or adjunct therapy for IP retinopathy. There is no sufficient evidence in the literature regarding its treatment outcomes, and it would be at the clinician's discretion to decide whether to use it based on the clinical context. Retinal detachment precautions should always be discussed with the patients during their visits. The decision of whether to choose EUA with FA at these annual appointments should depend on the patient's posttreatment course. Until more data are available to fully support stability without remission after ocular treatment, we suggest that EUA with FA should be performed at least once during the year after treatment and thereafter at the discretion of the physician given the clinical picture. This should also be done for those patients with vasculopathy who do not initially receive definitive treatment. In addition, the patient's mother should also be evaluated for IP retinopathy if she has not yet done so, regardless of their visual function status.
Lastly, we address the final branch of our management algorithm, the surgical treatment of patients who develop RD or grade 3 IP retinopathy. The surgical method is typically similar to the surgeries utilized for patients with ROP due to their similar ocular course if left untreated. 26 In a 1993 study reporting on the surgical treatment of several patients with IP who had developed RD, open-sky vitrectomy was (unsuccessfully) performed in a case of late-grade RD, whereas trans-pars plicata vitrectomy with membranectomy was performed for a less severe tractional RD with some preservation of functional vision. 26 Noting the paucity of data describing the results of retinal surgery in IP, the authors indicated that the reported success rates of 28% to 46% in vitreoretinal surgery in ROP could likely be extrapolated out to similar results in IP as well. The results of this systematic review show a 50% (2 of 4) success rate of surgical treatment and that laser is also an effective treatment option for RD associated with IP retinopathy.
Conclusions
This systematic review of the current literature is the first study of this kind to focus exclusively on the management of proliferative retinopathy associated with IP. The results of this study prompt us to propose an update on the management algorithm. We would recommend convening a committee of experts to create a new classification system for retinopathy associated with IP.
The study could be improved if we were able to include several foreign-text articles. As our experience with diagnosing and treating IP proliferative retinopathy continues to grow, and the diagnostic ocular imaging capability advances and the clinical phenotype-genotype correlation becomes more elucidated, the management algorithm will evolve accordingly to provide patients with the best chance to achieve their visual potential and prevent them from developing blindness.
